These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 20108995

  • 1. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
    Keating GM, Lyseng-Williamson KA.
    Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
    [Abstract] [Full Text] [Related]

  • 2. Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation.
    Keating GM, Lyseng-Williamson KA.
    CNS Drugs; 2010 Sep; 24(9):797-800. PubMed ID: 20806990
    [Abstract] [Full Text] [Related]

  • 3. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
    Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S.
    Clin Drug Investig; 2009 Sep; 29(10):655-65. PubMed ID: 19715382
    [Abstract] [Full Text] [Related]

  • 4. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD, Dugan SE.
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, Kyriopoulos J.
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [Abstract] [Full Text] [Related]

  • 6. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.
    Xenakis JG, Kinter ET, Ishak KJ, Ward AJ, Marton JP, Willke RJ, Davies S, Caro JJ.
    Pharmacoeconomics; 2011 Jun; 29(6):497-510. PubMed ID: 21452908
    [Abstract] [Full Text] [Related]

  • 7. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
    Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T.
    Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
    [Abstract] [Full Text] [Related]

  • 8. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
    Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens JW, Strong M, Cantrell A.
    Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822
    [Abstract] [Full Text] [Related]

  • 9. Varenicline in the management of smoking cessation: a single technology appraisal.
    Hind D, Tappenden P, Peters J, Kenjegalieva K.
    Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
    [Abstract] [Full Text] [Related]

  • 10. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation.
    Taylor M, Leonardi-Bee J, Agboola S, McNeill A, Coleman T.
    Addiction; 2011 Oct; 106(10):1819-26. PubMed ID: 21561499
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA, Lovato P, Cuesta G.
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [Abstract] [Full Text] [Related]

  • 12. Nicotine receptor partial agonists for smoking cessation.
    Cahill K, Stead LF, Lancaster T.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD006103. PubMed ID: 21154363
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of varenicline for smoking cessation.
    Keiding H.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun 08; 9(3):215-21. PubMed ID: 19527093
    [Abstract] [Full Text] [Related]

  • 14. Nicotine receptor partial agonists for smoking cessation.
    Cahill K, Stead LF, Lancaster T.
    Cochrane Database Syst Rev; 2012 Apr 18; (4):CD006103. PubMed ID: 22513936
    [Abstract] [Full Text] [Related]

  • 15. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
    Howard P, Knight C, Boler A, Baker C.
    Pharmacoeconomics; 2008 Apr 18; 26(6):497-511. PubMed ID: 18489200
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M, Welsing P, Rutten-van Mölken MP.
    Curr Med Res Opin; 2008 Jan 18; 24(1):51-61. PubMed ID: 18021492
    [Abstract] [Full Text] [Related]

  • 17. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, Varenicline Phase 3 Study Group.
    JAMA; 2006 Jul 05; 296(1):47-55. PubMed ID: 16820546
    [Abstract] [Full Text] [Related]

  • 18. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA, Lovato P, Cuesta G.
    Hosp Pract (1995); 2012 Feb 05; 40(1):35-43. PubMed ID: 22406881
    [Abstract] [Full Text] [Related]

  • 19. Nicotine receptor partial agonists for smoking cessation.
    Cahill K, Stead LF, Lancaster T.
    Cochrane Database Syst Rev; 2011 Feb 16; (2):CD006103. PubMed ID: 21328282
    [Abstract] [Full Text] [Related]

  • 20. Nicotine receptor partial agonists for smoking cessation.
    Cahill K, Stead LF, Lancaster T.
    Cochrane Database Syst Rev; 2008 Jul 16; (3):CD006103. PubMed ID: 18646137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.